Revenue Performance - Revenue for the six months ended June 30, 2022, was approximately HKD 63,516,000, a decrease of 12.6% compared to HKD 73,116,000 in the same period of 2021[8]. - The total revenue for the group during the reporting period was approximately HKD 63,500,000, down about 13.1% from HKD 73,100,000 in the same period last year[28]. - For the six months ended June 30, 2022, total revenue was HKD 63,516,000, a decrease of 13.1% compared to HKD 73,116,000 for the same period in 2021[98]. - Revenue from Hong Kong was HKD 58,056,000, down from HKD 66,662,000 in the previous year, representing a decline of 12.4%[106]. Profitability - The company reported a profit attributable to owners of the company of HKD 20,169,000, compared to a loss of HKD 27,083,000 in the same period last year[8]. - The gross profit for the group was approximately HKD 52,500,000, an increase of about 19.0% from HKD 44,100,000 year-on-year, resulting in a gross margin of approximately 82.7%[36]. - The company achieved a profit before tax of HKD 16,706,000, a significant recovery from a loss of HKD 31,654,000 in the prior year[71]. - The group reported a pre-tax profit of HKD 20,169,000 for the six months ended June 30, 2022, compared to a loss of HKD 27,083,000 for the same period in 2021[118]. - Total comprehensive income for the period was HKD 19,266,000, compared to a loss of HKD 31,455,000 in the previous year[71]. Segment Performance - The footwear business generated revenue of approximately HKD 61,951,000, a decline of 7.3% year-on-year, with same-store sales down by 2.6%[12][15]. - The healthcare segment recorded revenue of approximately HKD 200,000, down from HKD 600,000 in the same period of 2021 due to COVID-19 lockdowns in Australia[16]. - The financial services segment achieved revenue of approximately HKD 964,000, significantly lower than HKD 4,300,000 in the previous year, resulting in a net loss of HKD 1,800,000[18]. - The online medical services segment reported revenue of approximately HKD 400,000, a decrease of about 71.4% compared to HKD 1,400,000 in the same period last year, with a segment loss of HKD 5,000,000[19]. - The revenue breakdown includes sales of footwear products at HKD 61,951,000, health products at HKD 222,000, financial services at HKD 964,000, and online medical services at HKD 379,000[103]. Financial Position - The current liquidity ratio improved to 0.8 from 0.7, while the debt ratio decreased significantly to 116.1% from 311.8%[7]. - As of June 30, 2022, the group's bank deposits and cash amounted to approximately HKD 24,300,000, a decrease of about 8.9% from HKD 26,700,000 on December 31, 2021[41]. - The group's debt ratio as of June 30, 2022, was approximately 116.1%, a significant decrease from 311.8% on December 31, 2021, due to an increase in net assets and a reduction in current liabilities by approximately HKD 23,400,000[45]. - The total liabilities exceeded current assets by approximately HKD 26,781,000 as of June 30, 2022, an improvement from HKD 38,004,000 as of December 31, 2021[90]. - The total reported liabilities increased to HKD 146,517,000 as of June 30, 2022, compared to HKD 163,256,000 as of December 31, 2021, showing a decrease of 10.2%[108]. Operational Efficiency - Employee costs were approximately HKD 38,200,000, accounting for about 60.1% of revenue, compared to 55.8% in the same period last year[37]. - The average inventory turnover period increased to 346.9 days from 215.4 days, indicating potential inventory management challenges[7]. - The group incurred a net foreign exchange loss of HKD 1,077,000 and recognized a gain from property sales of HKD 32,959,000 during the reporting period[111]. - The group recognized a reversal of inventory provision amounting to HKD 13,162,000, which positively impacted the cost of sales[111]. - The company aims to enhance its operational efficiency and explore new strategies for market expansion[92]. Future Plans - The company plans to increase investment in the healthcare segment and strengthen partnerships with Australian natural health brands to develop high-margin products[12]. - The company aims to expand its presence in the health industry and identify new business development opportunities and acquisition targets[12]. - The group plans to expand its customer base in the footwear business while maintaining stable revenue in the second half of 2022[20]. - The online medical services division is transitioning to a post-startup phase, with plans to increase marketing efforts and expand sales performance[24]. - The company is considering the sale of existing properties and other assets to improve liquidity if appropriate[92]. Shareholder Information - The company’s major shareholder, Mr. Yang Jun, holds 61.77% of the issued share capital, amounting to 149,993,617 shares[14]. - Major shareholder TATA Health holds 149,993,617 shares, representing 61.77% of the company's issued share capital as of June 30, 2022[144]. - Great Wall International Investment X Limited holds 123,993,617 shares, accounting for 51.06% of the issued share capital, with these shares pledged to guarantee loans[145]. - The average number of ordinary shares weighted for the period was 242,845,000, compared to 221,012,044 shares in the previous year, reflecting an increase of 9.9%[118]. - The total number of issued and fully paid ordinary shares increased to 242,845,000 as of June 30, 2022, from 214,000,000 on January 1, 2021, due to a placement of 28,845,000 shares[13].
TATA健康(01255) - 2022 - 中期财报